<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00353080</url>
  </required_header>
  <id_info>
    <org_study_id>EFC6064</org_study_id>
    <secondary_id>HMR4003B/3001</secondary_id>
    <nct_id>NCT00353080</nct_id>
  </id_info>
  <brief_title>Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women</brief_title>
  <official_title>A Two-year, Multicenter, Double-blind, Randomized, Placebo-controlled and Parallel Group Study of Oral Risedronate 5 mg Daily in the Prevention of Osteoporosis in Osteopenic Postmenopausal Women (More Than 5 Years Postmenopausal)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To confirm the superiority of 5 mg daily risedronate as compared to placebo in maintaining or
      increasing bone mass in lumbar spine in osteopenic postmenopausal women

      To confirm the efficacy of 5 mg daily risedronate in osteopenic postmenopausal women in
      maintaining or increasing bone mass in proximal femur and decreasing bone resorption

      To confirm general safety of 5 mg daily risedronate as compared to placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent changes from baseline in lumbar spine bone mineral density (BMD) at Month 24 measured by DXA.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent changes in proximal femur BMD from baseline at month 12 and 24 (DXA)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of responders (subjects with a positive change in lumbar spine BMD from baseline)at Month 12 and 24</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent changes in bone turnover markers after 12 and 24 months of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination and hematology tests before and after 12 and 24 months of treatment;Serum Chemistry before and after 6, 12 and 24 months of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events at each visit with special interest for upper gastro-intestinal events</measure>
  </secondary_outcome>
  <enrollment type="Actual">171</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate (HMR4003)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory, healthy postmenopausal women with

               -  Natural menopause and more than 5 years after their last menstrual period

               -  or surgical menopause and more than 5 years after surgery

               -  osteopenia (lumbar spine T score between 1 and 2.5 SD below the mean value in
                  normal young women).

          -  With at least one risk factor for osteoporosis

        Exclusion Criteria:

          -  Women who have received hormone replacement therapy (with estrogen and/or progestogen
             and/or androgen) or raloxifene within 3 months before visit 2 or calcitonin or
             calcitriol within 4 weeks before visit 2
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Välimäki Matti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Endocrinology, Helsinki University Central Hospital, Helsinki, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial. Clin Ther. 2007 Sep;29(9):1937-49.</citation>
    <PMID>18035193</PMID>
  </results_reference>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2006</study_first_submitted>
  <study_first_submitted_qc>July 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2006</study_first_posted>
  <last_update_submitted>December 11, 2009</last_update_submitted>
  <last_update_submitted_qc>December 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Prevention of postmenopausal osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

